ArticleScience China. Life sciences2023

Design of a novel chimeric peptide via dual blockade of CD47/SIRPα and PD-1/PD-L1 for cancer immunotherapy.

Zheng Hu et al.PubMed ↗Publisher ↗

No numbers read from the abstract.